Summary
Around half of all patients do not take their treatment as prescribed. This ‘non-adherence’ to treatment can have a dramatic impact on patients’ health and quality of life, resulting in avoidable hospitalisations and contributing to an estimated 200 000 deaths annually in the EU.
Currently, we do not fully understand all the factors that influence patients’ decisions regarding their treatments. The BEAMER project aims to add to our understanding of the factors that influence patient adherence across disease areas, and deliver guidance that various stakeholders could use to address patients’ needs and boost adherence.
The project will create a model of the main factors affecting patient adherence to treatment and test it in pilot studies involving 18 000 patients in 6 countries. This will allow the project team to define non-adherence and develop guidance that healthcare stakeholders could transform into tools and solutions to improve adherence. The model will not be disease specific, but it will be possible for users to add disease-specific elements. This will make the model more widely applicable to different groups of patients.
Achievements & News
December 2021
Around half of all patient’s don’t take their treatment as prescribed. New Innovative Medicines Initiative (IMI) project BEAMER wants to...
Participants
Show participants on mapEFPIA companies
- Astellas Pharma Europe BV, Leiden, Netherlands
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Servier Affaires Medicales, Suresnes, France
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
- Akershus Universitetssykehus Hf, Lorenskog, Norway
- Echalliance Company Limited By Guarantee, Dublin, Ireland
- Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece
- Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
- Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany
- Klinikum Der Universitaet Zu Koeln, Cologne, Germany
- Servicio Madrileno De Salud, Madrid, Spain
- Tilburg University- Universiteit Van Tilburg, Tilburg, Netherlands
- Udg Alliance, Lausanne, Switzerland
- Universidad Politecnica De Madrid, Madrid, Spain
- Universitetet I Oslo, Oslo, Norway
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany
- Innovation Sprint, Bruxelles, Belgium
- Medida - Servicos Em Medicina, Educacao, Investigacao, Desenvolvimento E Avaliacao, Porto, Portugal
- Mysphera SL, Paterna, Spain
- Predictby Research And Consulting S.L., Barcelona, Spain
Patient organisations
- Associacao Protectora Dos Diabeticos De Portugal, Lisboa, Portugal
- Fondazione Italiana Sclerosi Multipla - Fism Ets, Genoa, Italy
- Stichting World Duchenne Organization, Veenendaal, Netherlands
Associated partners
- Link2trials BV, Hilversum, Netherlands
Third parties
- Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus, Madrid, Spain
- Fundacion Para La Investigacion E Innovacion Biosanitaria De Atencion Primaria, Madrid, Spain
| Participants | |
|---|---|
| Name | EU funding in € |
| Akershus Universitetssykehus Hf | 516 875 |
| Associacao Protectora Dos Diabeticos De Portugal | 255 938 |
| Echalliance Company Limited By Guarantee | 202 500 |
| Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh | 346 250 |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | 401 563 |
| Fondazione Italiana Sclerosi Multipla - Fism Ets | 220 625 |
| Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina | 40 938 |
| Heinrich-Heine-Universitaet Duesseldorf | 286 875 |
| Innovation Sprint | 343 750 |
| Klinikum Der Universitaet Zu Koeln | 25 938 |
| Medida - Servicos Em Medicina, Educacao, Investigacao, Desenvolvimento E Avaliacao | 176 250 |
| Mysphera SL | 231 750 |
| Open Evidence (left the project) | 63 340 |
| Predictby Research And Consulting S.L. | 631 223 |
| Servicio Madrileno De Salud | 64 688 |
| Stichting World Duchenne Organization | 266 406 |
| Tilburg University- Universiteit Van Tilburg | 422 813 |
| Udg Alliance | 260 625 |
| Universidad Politecnica De Madrid | 450 625 |
| Universidade Do Porto (left the project) | 123 997 |
| Universitetet I Oslo | 441 563 |
| Third parties | |
| Name | Funding in € |
| Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus | 110 812 |
| Fundacion Para La Investigacion E Innovacion Biosanitaria De Atencion Primaria | 63 563 |
| Total Cost | 5 948 907 |
Giuseppe Fico
Universidad Politecnica De Madrid